SELLAS Life Sciences (SLS) Income from Continuing Operations (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Income from Continuing Operations of 15053000.0 for Q1 2026, down 140.35% year-over-year from 37307850.81 in Q1 2025, and down 80.17% quarter-over-quarter from 8355000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Income from Continuing Operations for 15 consecutive years, with 15053000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 140.35% year-over-year to 15053000.0; the TTM figure through Mar 2026 stood at 39620000.0 (down 39.35% YoY), while the FY2025 annual figure was 51112000.0, up 2.42% from the prior year.
- Income from Continuing Operations fell to 15053000.0 in Q1 2026 per SLS's latest filing, from 8355000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6263000.0 in Q1 2025 and bottomed at 16835000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 9324411.76 across 5 years, with a median of 8723000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 617.91% — and 2025, when it soared 35.73%.
- SELLAS Life Sciences' Income from Continuing Operations stood at 9646000.0 in 2022, then advanced by 14.19% to 8277000.0 in 2023, then increased by 15.21% to 7018000.0 in 2024, then declined by 19.05% to 8355000.0 in 2025, then tumbled by 80.17% to 15053000.0 in 2026.
- Business Quant data shows SLS's Income from Continuing Operations at 15053000.0 in Q1 2026, 8355000.0 in Q4 2025, and 7283000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | -42.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.97 Mn |
| Mar 31, 2026 | -15.05 Mn |
| Dec 31, 2025 | -8.36 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -8.93 Mn |
| Mar 31, 2025 | -6.26 Mn |
| Dec 31, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.43 Mn |
| Jun 30, 2024 | -7.72 Mn |
| Mar 31, 2024 | -9.75 Mn |
| Dec 31, 2023 | -8.28 Mn |
| Sep 30, 2023 | -9.46 Mn |
| Jun 30, 2023 | -9.15 Mn |
| Mar 31, 2023 | -11.38 Mn |
| Dec 31, 2022 | -9.65 Mn |
| Sep 30, 2022 | -7.25 Mn |
| Jun 30, 2022 | -8.72 Mn |
| Mar 31, 2022 | -16.84 Mn |
| Dec 31, 2021 | -11.72 Mn |
| Sep 30, 2021 | -7.08 Mn |